LANTIDRAの新興薬剤に関する洞察と市場予測：2032年

LANTIDRA（donislecel）は、CellTransとイリノイ大学シカゴ校の共同研究により、脆化型1型糖尿病の治療薬として評価されている新規細胞治療薬です。donislecelは、経皮的あるいは経静脈的経肝アクセスにより、あるいはこれらが不可能な場合は腹腔鏡あるいは開腹手術により、肝門脈に注入されます。移植後、患者は移植片の機能、免疫抑制レベル、安全性をモニターされます。

今後数年間で、1型糖尿病の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病態を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、LANTIDRAの優位性に影響を与える可能性のある機会を模索しています。他の1型糖尿病治療薬も市場競合となることが予想され、近い将来、後発の治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるLANTIDRA市場について調査し、市場の概要とともに、2026年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 1型糖尿病に対するLANTIDRAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 LANTIDRA市場評価

• 1型糖尿病に対するLANTIDRAの市場展望
• 主要7ヶ国市場分析
  • 主要7ヶ国における1型糖尿病に対するLANTIDRAの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: LANTIDRA, Clinical Trial Description, 2023
• Table 2: LANTIDRA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: LANTIDRA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: LANTIDRA Market Size in the US, in USD million (2019-2032)
• Table 7: LANTIDRA Market Size in Germany, in USD million (2019-2032)
• Table 8: LANTIDRA Market Size in France, in USD million (2019-2032)
• Table 9: LANTIDRA Market Size in Italy, in USD million (2019-2032)
• Table 10: LANTIDRA Market Size in Spain, in USD million (2019-2032)
• Table 11: LANTIDRA Market Size in the UK, in USD million (2019-2032)
• Table 12: LANTIDRA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: LANTIDRA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: LANTIDRA Market Size in the United States, USD million (2019-2032)
• Figure 3: LANTIDRA Market Size in Germany, USD million (2019-2032)
• Figure 4: LANTIDRA Market Size in France, USD million (2019-2032)
• Figure 5: LANTIDRA Market Size in Italy, USD million (2019-2032)
• Figure 6: LANTIDRA Market Size in Spain, USD million (2019-2032)
• Figure 7: LANTIDRA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: LANTIDRA Market Size in Japan, USD million (2019-2032)

“"LANTIDRA Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LANTIDRA for type 1 diabetes mellitus in the seven major markets. A detailed picture of the LANTIDRA for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LANTIDRA for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LANTIDRA market forecast analysis for type 1 diabetes mellitus in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary:

LANTIDRA (donislecel) is a novel cellular therapy being evaluated for use in brittle type 1 diabetes through a collaborative effort between CellTrans and the University of Illinois at Chicago. Donislecel is infused into the hepatic portal vein via percutaneous or transvenous transhepatic access, or if these are not feasible, then via laparoscopic or open surgical access. Following the transplant, the patient is monitored for graft function, immunosuppression levels, and safety.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the LANTIDRA description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
• Elaborated details on LANTIDRA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LANTIDRA research and development activities in type 1 diabetes mellitus across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around LANTIDRA.
• The report contains forecasted sales of LANTIDRA for type 1 diabetes mellitus till 2032.
• Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
• The report also features the SWOT analysis with analyst views for LANTIDRA in type 1 diabetes mellitus.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LANTIDRA Analytical Perspective by DelveInsight

In-depth LANTIDRA Market Assessment

This report provides a detailed market assessment of LANTIDRA for type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

LANTIDRA Clinical Assessment

The report provides the clinical trials information of LANTIDRA for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LANTIDRA dominance.
• Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to LANTIDRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LANTIDRA in type 1 diabetes mellitus.
• Our in-depth analysis of the forecasted sales data of LANTIDRA from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LANTIDRA in type 1 diabetes mellitus.

Key Questions:

• What is the product type, route of administration and mechanism of action of LANTIDRA?
• What is the clinical trial status of the study related to LANTIDRA in type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LANTIDRA development?
• What are the key designations that have been granted to LANTIDRA for type 1 diabetes mellitus?
• What is the forecasted market scenario of LANTIDRA for type 1 diabetes mellitus?
• What are the forecasted sales of LANTIDRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to LANTIDRA for type 1 diabetes mellitus?
• Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?

Table of Contents

1. Report Introduction

2. LANTIDRA Overview in type 1 diabetes mellitus

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. LANTIDRA Market Assessment

• 5.1. Market Outlook of LANTIDRA in type 1 diabetes mellitus
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of LANTIDRA in the 7MM for type 1 diabetes mellitus
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of LANTIDRA in the United States for type 1 diabetes mellitus
  • 5.3.2. Market Size of LANTIDRA in Germany for type 1 diabetes mellitus
  • 5.3.3. Market Size of LANTIDRA in France for type 1 diabetes mellitus
  • 5.3.4. Market Size of LANTIDRA in Italy for type 1 diabetes mellitus
  • 5.3.5. Market Size of LANTIDRA in Spain for type 1 diabetes mellitus
  • 5.3.6. Market Size of LANTIDRA in the United Kingdom for type 1 diabetes mellitus
  • 5.3.7. Market Size of LANTIDRA in Japan for type 1 diabetes mellitus

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options